Unhidea explains global investment research, selected interviews and market briefs. Explore source attribution, dates, key assumptions and the reasoning behind each article.
Morgan Stanley says Hengrui’s third-quarter revenue and profit were both slightly above market consensus: innovative drug sales accelerated and recognized collaboration revenue increased, but generic drug sales continued to decline and product gross margin also fell.
Morgan Stanley ·
Nomura estimates that Hengrui's third-quarter drug sales grew 4.9% year on year, reversing the previous quarter's decline. A sharp increase in collaboration revenue pushed total revenue and net profit attributable to shareholders above Bloomberg consensus estimates, although full-year growth in innovative drug sales may fall short of the company's target set at the start of the year.
Nomura ·
A HER2 ADC achieved median progression-free survival of 16.4 months in a Chinese phase III breast cancer trial, but a weaker control group and a higher incidence of serious adverse reactions limit cross-trial comparisons; data from the HER3 ADC and KRAS G12D programs met Morgan Stanley’s expectations.
Morgan Stanley ·
